VDI
GILD icon

Vaughan David Investments’s Gilead Sciences GILD Stock Holding History

Vaughan David Investments’s Portfolio GILD Stock Details GILD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$37M Buy
293,037
+8,552
+3% +$1.13M 0.74% 68
2026
Q1 		$39.6M Buy
284,485
+9,094
+3% +$1.27M 0.84% 62
2025
Q4 		$33.8M Buy
+275,391
New +$33.5M 0.74% 70

Other funds holding GILD

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Vaughan David Investments's GILD Position: Q2 2026 in Review

Vaughan David Investments increased its Gilead Sciences (GILD) stake by 3% in Q2 2026, buying an estimated $1.13M and bringing the position to 293,037 shares worth $37M. The position accounts for 0.74% of the portfolio, ranked #68.

Vaughan David Investments first reported a position in GILD in Q4 2025 and has held it in 3 quarters since. The position peaked at $39.6M in Q1 2026. 2,284 funds tracked by Wall St. Rank hold GILD as of Q2 2026.

  • Vaughan David Investments held 293,037 shares of Gilead Sciences worth $37M as of Q2 2026.
  • Vaughan David Investments bought 8,552 Gilead Sciences shares in Q2 2026, an estimated $1.13M.
  • Gilead Sciences made up 0.74% of Vaughan David Investments's portfolio in Q2 2026, its #68 holding.
  • Vaughan David Investments first reported a position in Gilead Sciences in Q4 2025 and has held it in 3 quarters since.
  • Vaughan David Investments's Gilead Sciences position peaked at $39.6M in Q1 2026.
  • 2,284 funds tracked by Wall St. Rank held Gilead Sciences as of Q2 2026.

Based on Vaughan David Investments's 13F filing for Q2 2026, filed 11 Aug 2026.